We are looking at HitPaw FotorPea, which is a handy AI image upscaler that can enhance, restore, or improve your images with a natural look.

Explore the leading data orchestration platforms for 2026 with quick comparisons, practical selection tips, and implementation guidance to keep your data pipelines reliable and scalable.

FORT WORTH, TX, UNITED STATES, January 29, 2026 /EINPresswire.com/ — Vadzo Imaging, a leading company in global embedded vision solutions, is pleased to introduce the Falcon-235MGS Global Shutter ...

AT&T's chief data officer shares how rearchitecting around small language models and multi-agent stacks cut AI costs by 90% at 8 billion tokens a day.

As of February 2026, face swap technology has moved far beyond novelty filters. After testing 15+ platforms across photos and videos, I've found tools that ...

Samsung’s One UI 8.5 beta revamps Bixby into a more conversational device agent and adds Perplexity-powered web answers in select regions.

Speechify's Voice AI Research Lab Launches SIMBA 3.0 Voice Model to Power Next Generation of Voice AI SIMBA 3.0 represents a major step forward in production voice AI. It is built voice-first for ...

Red Hat Inc. said today it’s gearing up its artificial intelligence ambitions with the launch of a new platform called Red Hat AI Enterprise that’s meant to make it easier to deploy and manage models, ...

Meta has quietly launched its $2 billion acquisition, Manus, as an autonomous AI agent on Telegram. Discover how this "action engine" builds apps, analyzes data, and browses the web for you.

Discover the 7 best cloud orchestration tools for enterprises in 2026, including AWS CloudFormation, Ansible, Spacelift, CloudBolt, and more. Compare features, pricing, multi-cloud support, and use ...

After adding image generation to Duck.ai late last year, DuckDuckGo is now rolling out image editing capabilities for its private AI chatbot.

China’s brain-computer interface industry is rapidly scaling from research to commercialization, driven by strong policy support, expanding clinical trials, and growing investor interest.